by Laura A. Huppert  , Marie Sinclair  and Jennifer C. Lai

Received: 08 November 2018;  Published: 28 November 2018;  doi: 10.21926/obm.transplant.1804028

Background: Patients with cirrhosis suffer not only from commonly-diagnosed portal hypertensive complications such as ascites and hepatic encephalopathy but also from more insidious effects of chronic liver failure including muscle wasting, under-nutrition, and functional decline. These manifestations of physical frailty have been demonstrated to predict mortality in patients with cirrhosis independently of liver disease severity, but objective biomarkers associated with physical frailty in cirrhosis are needed. Th [...]

by Yujie Wen  , Anita Y. Chhabra  , Joseph R. Leventhal  and Suzanne T. Ildstad

Received: 29 October 2018;  Published: 20 November 2018;  doi: 10.21926/obm.transplant.1804027

This review summarizes the latest results from the interventional clinical trials for inducing clinical tolerance in the recipients of human leukocyte antigen (HLA)-matched or mismatched living donor kidney transplants via allogeneic hematopoietic stem cell (HSC)-based therapies. The protocols utilized by the three medical centers in the United States differ in degree of HLA-matching, relatedness or unrelatedness, donor cell composition of the hematopoietic stem cells transplant (HSCT), timing for infusion and cond [...]

by Maria Irene Bellini  , Joseph Ayathamattam  and Paul Elliot Herbert

Received: 19 October 2018;  Published: 19 November 2018;  doi: 10.21926/obm.transplant.1804026

Obesity is on the rise and the number of end stage renal disease patients who are obese parallel this trend. There is no universally accepted guideline for wait-listing end stage renal disease obese patients in order to reduce surgical complications and improve survival of the kidney graft. Criteria for acceptance are variable among transplant centres, as do post-transplant policies. Careful risk assessment to maximise the benefits of the limited organ donor resource must be undertaken prior to waitlist an obese ki [...]

by Sylvaine You  and Lucienne Chatenoud

Received: 25 September 2018;  Published: 09 November 2018;  doi: 10.21926/obm.transplant.1804025

Transplant tolerance has been achieved in experimental models using immune intervention strategies. Yet, their clinical translation remains unsuccessful and requires further optimization of immunotherapeutic regimens based on a deeper understanding of the cellular and molecular mechanisms at play in the induction and maintenance phases of immune tolerance. Intensive investigations have shed light on the tolerogenic networks underlying graft survival and have unraveled their complexity, which may depend on several p [...]

by Robert C. McCarthy  , Michael L. Green  and Francis E. Dwulet

Received: 24 September 2018;  Published: 07 November 2018;  doi: 10.21926/obm.transplant.1804024

Islet transplantation is becoming an established treatment option for managing a subset of adult patients who have type 1 diabetes mellitus. The success of this procedure is dependent upon the recovery of a sufficient number of functional human islets from donor organs for subsequent transplant. Here, the use of optimized bacterial collagenase-neutral protease enzyme mixtures has been shown to affect the yield and quality (defined by viability and glucose-stimulated insulin secretion) of islets recovered from human [...]

by Masayuki Nigo  , Rodrigo Hasbun  and Karen J Vigil

Received: 29 March 2018;  Published: 02 November 2018;  doi: 10.21926/obm.transplant.1804023

Liver transplantation is a life-saving procedure available worldwide. Despite advances in its surgical and immunosuppressive strategies, infectious complications carry significant morbidity and mortality. Bacterial infections are the most common infective etiologies, and the majority are seen during the first four weeks post liver transplantation. Infectious complications are often intra-abdominal in origin, such as biliary complications and abdominal abscesses. Infections due to multi-drug resistant organisms are [...]

by Alicia M Teagarden  , Emma M Tillman  and Courtney M Rowan

Received: 24 April 2018;  Published: 29 October 2018;  doi: 10.21926/obm.transplant.1804022

Background: Hematopoietic cell transplant (HCT) patients are a high-risk population for poor nutrition and decreased survival. There is little data on how nutrition in pediatric HCT patients affects need for critical care interventions and outcomes. Methods: We hypothesized that patients who did not meet goal nutrition by 72 hours post-admission to the pediatric intensive care unit (PICU) had increased in-hospital mortality and increased need for critical care interventions. We performed a retrospective cohort stud [...]

by Wasim A. Dar

Received: 03 September 2018;  Published: 29 September 2018;  doi: 10.21926/obm.transplant.1803021

liver transplantation

by Ashley Rosenberg  , Gilles Dongmo  , Pallavi Yadav  , Nathaniel Lee  and Kunal Yadav

Received: 13 August 2018;  Published: 21 September 2018;  doi: 10.21926/obm.transplant.1803020

Even though renal ectopia is common, there have been very few reports of these kidneys being used for transplantation. The concerns with using such kidneys are subnormal function, ureteral anomalies and complications and anomalous arterial supply which makes arterial reconstruction challenging. Majority of reports are for use in living donor transplantation where good preoperative imaging is available. There is very scant literature reporting use of ectopic pelvic kidneys from deceased donors. We report a case of a [...]

by Dayu Lv  , Jose Garcia-Tirado  and Chiara Fabris

Received: 17 May 2018;  Published: 11 September 2018;  doi: 10.21926/obm.transplant.1803019

Background: Human pancreatic islet transplantation is a minimally-invasive procedure that is gaining recognition for the treatment of type 1 diabetes (T1D). Selected patients with unstable T1D, hypoglycemia unawareness, history of severe hypoglycemia, and glycemic lability, not successfully stabilized with intensive insulin treatment, can be offered this alternative therapy that has been shown to provide long-term glycemic control with near-normalization of hemoglobin A1c in the absence of severe hypoglycemia. Toda [...]